All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 176 of 206 pages ‹ First < 174 175 176 177 178 > Last ›
HSL648
Wilkes MS, Kravitz RL.
Policies, practices, and attitudes of North American medical journal editors.
J Gen Intern Med 1995 Aug;10:(8):443-50
HSL650
Tong KL, Lien CY.
Do pharmaceutical representatives misuse their drug samples?
Can Fam Physician 1995 Aug;41:1363-6:
HSL6594
Parke-Davis claims Ponstan “provides unsurpassed efficacy comared to acetominophen in fever control”
MaLAM International News 1995 Aug;13:(8):1-2
HSL6595
Lexchin J.
Re: the promotion of Ponstan (mefenamic acid)
1995 Aug;
HSL6596
Pitkin RM.
Conflict of interest revisited.
Obstet Gynecol 1995 Aug;86:(2):293
http://www.greenjournal.org/cgi/reprint/86/2/293
HSL6597
Roughead EE
The pharmaceutical representative and medical practitioner encounter: implications for quality use of medicines
1995 Aug
www.camtech.net.au/malam
HSL9214
Lawrence DB, Weart CW.
HMO pharmacy directors' opinions of acquisition of pharmacy benefit management companies.
Am J Health Syst Pharm 1995 Jul 15;52:(14):1547-9
HSL5312
Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al.
Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.
JAMA 1995 Jul 5;274:(1):29-34
HSL683
Evans RG.
Manufacturing consensus, marketing truth: guidelines for economic evaluation.
Ann Intern Med 1995 Jul 1;123:(1):59-60
HSL5755
Commisso JT.
Errors and biases in clinical judgment
Dissertation-Abstracts-International:-Section-B:-The-Sciences-and -Engineering. 1995 Jul 1;56:(1-B):
HSL9200
Garattini S.
Cultural shift in Italy's drug policy.
Lancet 1995 Jul 1;346:(8966):5-6
HSL16280
Van Trigt AM, Haaijer-Ruskamp FM, de Jong-van den Berg LT.
Reporting research in medical journals and newspapers.
BMJ 1995 Jul 1;311:(6996):62
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7677871
HSL1450
Bickell NA.
Drug companies and continuing medical education.
J Gen Intern Med 1995 Jul;10:(7):392-4
HSL6591
MaLAM Letter follow up—antidiarrhoeals
MaLAM International News 1995 Jul;13:(7):2
HSL6593
Lexchin J.
Re: the promotion of Polymagma (attapulgite)
1995 Jul;
HSL9187
Woodward BW.
Disease management: opportunity for pharmaceutical care?
Hosp Pharm 1995 Jul;30:(7):596,
HSL2335
Shorr RI, Greene WL.
A food-borne outbreak of expensive antibiotic use in a community teaching hospital.
JAMA 1995 Jun 28;273:(24):1908
http://jama.ama-assn.org/cgi/search?pubdate_year=&volume=&firstpage=&author1=Shorr%2C+R+&author2=Greene%2C+W&title=&andorexacttitle=and&titleabstract=&andorexacttitleabs=and&fulltext=&andorexactfulltext=and&fmonth=Jan&fyear=1966&tmonth=Aug&tyear=2005&fdatedef=3+January+1966&tdatedef=24+August+2005&tocsectionid=all&COLLECTION_NUM=&flag=&RESULTFORMAT=1&hits=10&hitsbrief=25&sortspec=relevance&sortspecbrief=relevance&sendit=Search
HSL672
La Puma J, Stocking CB, Rhoades WD, Darling CM, Ferner RE, Neuberger J, VandenBurg M, Dews I, Tobias JS.
Financial ties as part of informed consent to postmarketing research. Attitudes of American doctors and patients
BMJ 1995 Jun 24;310:1660-1661
http://www.bmj.com/cgi/content/full/310/6995/1660
HSL1447
Brophy JM.
Medical newsletters: funding and interests should be stated.
CMAJ 1995 Jun 1;152:(11):1744-5
HSL6587
Lexchin J, Vitry A.
MaLAM Letter follow up—Sandoz’s promotion of Parlodel (bromocriptine)
MaLAM International News 1995 Jun;13:(6):1-8
HSL6588
Mansfield P.
Are pharmaceutical customers prey or partners?
Scrip Magazine 1995 Jun;(36):14-15
www.pjbpubs.co.uk/scrip/scrhome.html
HSL6589
Vitry A.
Rhône-Poulenc Rorer claims that their promotional material “is well balanced and answers the needs of the clinician with regard to both safety and efficacy”
MaLAM Australian News 1995 Jun;3:(6):1-4
HSL9175
Wechsler J.
Information explosion
Pharmaceutical Executive 1995 Jun;15:16, 18, 20
HSL9177
Harvey M.
Defending the powerless patient
Pharmaceutical Executive 1995 Jun;15:28, 32
HSL9225
Rothermich EA, Pathak DS.
Evaluation of quality of life appeals in prescription drug advertisements
1995 Jun;52:
HSL8373
Griffith WA, Cangemi RR.
Direct-to-consumer Rx ads? Drug firms see pluses, minuses
Drug Topics 1995? May 20;129:60-61
HSL9198
Program for patient packs by 1999 unveiled
Pharmaceutical Journal 1995 May 20;245:679
HSL5324
Crawshaw R, Rogers DE, Pellegrino ED, Bulger RJ, Lundberg GD, Bristow LR, Cassel CK, Barondess JA.
Patient-physician covenant.
JAMA 1995 May 17;273:(19):1553
HSL663
Nikelly AG.
Drug advertisements and the medicalization of unipolar depression in women.
Health Care Women Int 1995 May-Jun;16:(3):229-42
HSL6582
Hoechst to discontinue Baralgin (dipyrone/pitofenone/fenpiverinium)
MaLAM International News 1995 May;13:(5):2
HSL6583
Servier claims Coversyl is “the only ACE inhibitor proven to remodel hypertensive arteries and control blood pressure throughout 24 hours after a single daily dose”
MaLAM Australian News 1995 May;3:(5):1-2
HSL6584
Lexchin J.
Re: the promotion of Arcalion (sulbutiamine) and Duxaril (almitrine/raubasine)
1995 May;
HSL6585
Vitry A.
Re: the promotion of Coversyl (perindopril)
MaLAM Australian News 1995 May;
HSL6586
Philippine College of Physicians issues guidelines on pharmaceutical promotions
Drug Monitor 1995 May-Jun;10:(3):26-27
HSL9182
Sutherland K.
Prescription for pain promotion
Australian Journal of Pharmacy 1995 May;76:443-445
HSL9206
Griffin JP.
Pharmaceutical industry of the future
International Pharmacy Journal 1995 May-Jun;9:
HSL9207
Bergman LC.
Prescription for successful marketing: indys put coupons in the mail
Drug Store News for the Pharmacist 1995 May;5:57
HSL9211
Gibaldi M.
Vertical integration: the drug industry and prescription benefits managers.
Pharmacotherapy 1995 May-Jun;15:(3):265-71
HSL645
Ziegler MG, Lew P, Singer BC.
The accuracy of drug information from pharmaceutical sales representatives.
JAMA 1995 Apr 26;273:(16):1296-8
HSL653
Stryer DB, Bero LA.
Drug promotion.
N Engl J Med 1995 Apr 13;332:(15):1032
HSL664
Mossinghoff GJ.
Drug promotion.
N Engl J Med 1995 Apr 13;332:(15):10
HSL670
La Puma J.
Drug promotion.
N Engl J Med 1995 Apr 13;332:(15):1031
HSL674
Kalish RS.
Drug promotion.
N Engl J Med 1995 Apr 13;332:(15):1032
HSL678
Hoberman D.
Drug promotion.
N Engl J Med 1995 Apr 13;332:(15):1031
HSL691
Cohen SN.
Drug promotion.
N Engl J Med 1995 Apr 13;332:(15):1032
HSL20217
Barber N
What constitutes good prescribing?
BMJ 1995 Apr 8;310:
http://www.bmj.com/content/310/6984/923.full
HSL19802
Hazinski TA
Which research results should the public believe?
NEJM 1995 Apr 6;332:(14):963
http://www.nejm.org/doi/full/10.1056/NEJM199504063321420
HSL690
Colby WD.
Guidelines for interaction with the pharmaceutical industry.
CMAJ 1995 Apr 1;152:(7):1040-2
HSL5350
Naylor CD.
Grey zones of clinical practice: some limits to evidence-based medicine.
Lancet 1995 Apr 1;345:(8953):840-2
HSL665
Mainous AG 3rd, Hueston WJ, Rich EC.
Patient perceptions of physician acceptance of gifts from the pharmaceutical industry.
Arch Fam Med 1995 Apr;4:(4):335-9
HSL6580
SmithKline Beecham claims Augmentin provides: “success that rises above resistance”
MaLAM International News 1995 Apr;13:(4):1-2
HSL6581
Pye J.
Knowledge is the best medicine
Scrip Magazine 1995 Apr;(34):20
HSL15821
Benson MK.
Review of Medicine, money and morals: physicians' conflicts of interest
J Med Ethics 1995 Apr;21:(2):24
http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=1376649&pageindex=1
HSL16726
Ahmad SR, Wolfe SM.
Advertising in Pediatrics.
Pediatrics 1995 Apr;95:(4):617-8
http://www.ncbi.nlm.nih.gov/pubmed/7700772
HSL16281
van Trigt AM, de Jong-van den Berg LT, Pasman M, Haaijer-Ruskamp FM, Willems J, Tromp TF.
Information about drugs in family magazines.
Pharm World Sci 1995 Mar 24;17:(2):48-53
http://www.ncbi.nlm.nih.gov/pubmed/7795558
HSL671
La Puma J.
Physician rewards for postmarketing surveillance (seeding studies) in the US.
Pharmacoeconomics 1995 Mar;7:(3):187-90
HSL6575
Astra initiates public education campaign to reduce use of medicines
PMAC News 1995 Mar;5-6
HSL6576
SmithKline Beecham claims Halfan is “effective in all types of malaria” and has an “excellent safety profile”
MaLAM International News 1995 Mar;13:(3):1-2
HSL6577
Lexchin J.
Re: the promotion of Halfan (halofantrine)
1995 Mar;
HSL6578
Mansfield P.
Merck Sharp & Dohme claim “we have conducted our promotion of Zocor very responsibly and ethically”
MaLAM Australian News 1995 Mar;3:(3):1-6
HSL6579
Now—two Benadryls!
Drug Monitor 1995 Mar-Apr;10:(2):17-18
HSL9176
Drugs (prices control) order 1995
Eastern Pharmacist 1995 Mar;38:51-57
HSL9181
Bootman JL, Noel M.
Sampling on the line: should the giveaway war come to an end?
Pharmaceutical Executive 1995 Mar;15:86, 88, 90
HSL9192
Farmer K, Jacobs E.
PILOT STUDY OF THE IMPACT ON PATIENT MEDICATION ADHERENCE BY A COMPANY SPONSORED NEWSLETTER COMPLIANCE PROGRAM
1995 Mar;142:24
HSL9193
Basara LR, Smith MC, Banahan BF, Juergens JP, Sloan H.
PROFILE OF CONSUMERS WHO ARE AWARE OF AND REACT TO DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION MEDICINES
1995 Mar;42:51
HSL9194
Zgarrick DP, Reutzel TJ.
PHARMACY'S ROLE IN MEETING THE NEEDS OF PATIENTS WHO CANNOT AFFORD THEIR MEDICATIONS: MEDS DUPAGE EXPERIENCE
1995 Mar;42:69
HSL9195
Christensen TP, Ascione FJ.
EFFECT OF DIRECT TO CONSUMER ADVERTISING IN AN ELDERLY POPULATION
1995 Mar;42:145
HSL9196
Chukkapalli RM, Kolassa EM, Taylor TH, Ogilvie S.
15-YEAR TREND IN LAUNCH PRICES FOR OUTPATIENT PRESCRIPTION MEDICATIONS
1995 Mar;42:53
HSL9205
Weisbach JA, Moos WH.
Diagnosing the decline of major pharmaceutical research laboratories: prescription for drug companies
Drug Development Research 1995 Mar;34:243-259
HSL9212
Simonsen LL.
Top 200 drugs of 1994: Rx prices still moderating as managed care grows
Pharmacy Times 1995 Mar;61:17-20, 22-23
HSL6574
Selling disease
Canadian Broadcasting Corporation program Marketplace 1995 Feb 75
HSL6570
Action on unethical drug promotion at World Health Assembly
INRUD News 1995 Feb;5:(1):22
HSL6571
Rhône-Poulenc Rorer claims Orudis SR has “high GI tolerance” and “can provide your arthritis patients with another dimension in pain relief”
MaLAM Australian News 1995 Feb;3:(2):1-2
HSL6572
Lexchin J.
Re: the promotion of Ashton & Parsons Infants’ Powders (chamomile extract)
1995 Feb;
HSL6573
Mansfield P.
Re: the promotion of Orudis (ketoprofen)
1995 Feb;
HSL9190
Top 200
American Druggist 1995 Feb;211:20-24
HSL9204
Schwartz H.
Shifting sands of time
Pharmaceutical Executive 1995 Feb;15:20, 22
HSL654
Siwek J.
Buying Editorials.
N Engl J Med 1995 Jan 19;332:(3):194
HSL659
Rapp MS.
Size of names in drug ads.
CMAJ 1995 Jan 15;152:(2):158
HSL9213
Conlan MF.
Contract for compliance
1995 Jan 9;139:66, 68
HSL661
Rapoport D.
Physicians and the pharmaceutical industry: under the influence?
CMAJ 1995 Jan 1;152:(1):15
HSL669
Lal A, Sethi A, Ray A.
Informing patients about drugs.
Natl Med J India 1995 Jan-Feb;8:(1):36-8
HSL6567
Sandoz claims that for suppressing lactation “Parlodel is still the most extensively studied, the most effective and the one with the most favourable ratio of benefit to risk”
MaLAM International News 1995 Jan;13:(1):1-2
HSL6568
Lexchin J.
Re: the promotion of Parlodel (bromocriptine)
1995 Jan;
HSL6569
Mansfield P.
Re: the promotion of Ciproxin (ciprofloxacin)
1995 Jan;
HSL9186
Marks HM.
Revisiting "the origins of compulsory drug prescriptions".
Am J Public Health 1995 Jan;85:(1):109-15
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7832245
HSL16727
Wolfe S
Unhealthy Charities
Lancet 1995 Jan;
HSL5404
Vinicky JK, Edwards SS, Orlowski JP.
Conflicts of interest, conflicting interests, and interesting conflicts.
J Clin Ethics 1995 Win 01;6:(4):358-66
HSL364
Lexchin J.
Deception by design: Pharmaceutical promotion in the Third World
Penang: Consumers International 1995
HSL646
Wooller HO.
Product information: a pharmaceutical industry perspective
Australian Prescriber 1995;18:19-20
HSL647
Williams PA, Cockerill R, Lowy FH.
The physician as prescriber: relations between knowledge about prescription drugs, encounters with patients and the pharmaceutical industry, and prescription volume
Health and Canadian Society 1995;3:135-166
HSL651
Toal CB, Borkowski KR.
The pharmaceutical industry, the Canadian Society for Clinical Pharmacology and academe: a partnership in health care
Can J Clin Pharmacol 1995;2:(2):49
HSL652
Taylor SD, Sullivan DL, Birdwell SW.
A comparative analysis of prescription drug advertising before and after patent expiration
J Pharm Mark Manage 1995;9:(4):3-18
HSL656
Seger M, Cobby J.
Survey of an industry-based medical information system
Canadian Pharmaceutical Journal 1995;127:(10):39-43
HSL658
Reinstein JA.
OTC advertising: in whose interest? The manufacturer’s viewpoint
WHO Drug Information 1995;9:(1):11-13
HSL660
Rapoport D.
Under the influence of the pharmaceutical industry? Kick the habit.
CMAJ 1995;152:1043
HSL662
Petroshius SM, Titus PA, Hatch KJ.
Physician attitudes toward pharmaceutical advertising
J Advert Res 1995;35:(6):41-51
HSL667
Lexchin J.
Is there a bias in industry supported clinical research
Can J Clin Pharmacol 1995;2:15-18
HSL668
Landefeld CS, Chren MM, Siddique RM.
A 4-year study of the volume of drug advertisements in leading medical journals
N Engl J Med 1995;10:(Supp):111
HSL675
Horton R.
Bayer accused of disinformation
Lancet 1995;346:891
Page 176 of 206 pages ‹ First < 174 175 176 177 178 > Last ›
